利伐沙班用于预防髋关节置换术后下肢深静脉栓塞的临床观察

The Clinical Observation of Rivaroxaban to Prevent Deep Venous Thrombosis Following Total Hip Arthroplasty

目的观察利伐沙班对髋关节置换术后下肢深静脉栓塞(DVT)的预防效果。方法将83例行髋关节置换术后患者随机分为A、B两组,A组42例,B组41例。A组应用利伐沙班口服,实用时间为14d;B组应用低分子肝素(LMWH),使用时间为14d。比较两组的疗效结果。两组在治疗期间均无严重出血。结果 A组出现DVT 2例(4.76%),B组出现DVT 2例(4.87%),A组DVT发生率与B组相当,差异无统计学意义(P>0.05)。结论利伐沙班用于预防髋关节置换术后下肢深静脉栓塞效果良好。利伐沙班在预防全髋置换后下肢深静脉血栓的疗效与安全性上与低分子肝素作用相当。

Objective To observe the clinical effects ofrivaroxaban against DVT after total hiparthroplasty. Methods Totally 83 THA patients were random divided into two groups. Rivaroxaban were used on group A （42 cases） for 14 days. LMWH were used on group B （41 cases） for 14 days. Results There was no intraopemfive bleeding between the two groups. The incidence rate of deep vein thrombosis in the rivaroxaban treatment group was 4.76% （2 cases） . The incidence rate of deep veinthrombosis in the LMWH treatment group was 4.87% （2 cases） . There was no statistics differences in DVT prevention and between the two groups （P〉0.05） . Conclusion Rivaroxaban had good efficacy on DVT prevention after total hip arthroplasty. Rivaroxaban had similar effects and security to LMWH on DVT prevention after THA.